About Castle Biosciences
Castle Biosciences is a company based in Friendswood (United States) founded in 2008.. Castle Biosciences has raised $61.97 million across 17 funding rounds from investors including SVB, BrightEdge and Industry Ventures. The company has 761 employees as of December 31, 2024. Castle Biosciences has completed 3 acquisitions, including AltheaDx, Castle Biosciences and Previse. Castle Biosciences offers products and services including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix. Castle Biosciences operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics, DermTech and Unity Biotechnology, among others.
- Headquarter Friendswood, United States
- Employees 761 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Castle Biosciences, Inc.
-
Annual Revenue
$332.07 M51.09as on Dec 31, 2024
-
Net Profit
$18.25 M131.76as on Dec 31, 2024
-
EBITDA
$24.67 M144.33as on Dec 31, 2024
-
Total Equity Funding
$61.97 M (USD)
in 17 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jul 29, 2019
-
Investors
SVB
& 4 more
-
Employee Count
761
as on Dec 31, 2024
-
Investments & Acquisitions
AltheaDx
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Castle Biosciences
Castle Biosciences is a publicly listed company on the NASDAQ with ticker symbol CSTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Assesses risk of melanoma metastasis for treatment guidance.
Evaluates metastasis risk in squamous cell carcinoma patients.
Predicts progression risk for Barrett's esophagus to cancer.
Guides mental health medication based on genetic profiles.
Unlock access to complete
Unlock access to complete
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $61.97M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 17
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(20 Mar 2009)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2019 | Amount | Post-IPO - Castle Biosciences | Valuation |
investors |
|
| Mar, 2019 | Amount | Series F - Castle Biosciences | Valuation | BrightEdge |
|
| May, 2018 | Amount | Series F - Castle Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Castle Biosciences
Castle Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, BrightEdge and Industry Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BrightEdge is focused on impact investment in cancer care innovation.
|
Founded Year | Domain | Location | |
|
Investments in private tech ecosystem are made by Industry Ventures.
|
Founded Year | Domain | Location | |
|
Investments are focused on tech and life sciences startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Castle Biosciences
Castle Biosciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AltheaDx, Castle Biosciences and Previse. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer detection and prevention solutions are developed by Previse.
|
2018 | ||||
|
Molecular diagnostics and biomarker discovery services are offered.
|
2009 | ||||
|
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Castle Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Castle Biosciences Comparisons
Competitors of Castle Biosciences
Castle Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics, DermTech and Unity Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Castle Biosciences
Frequently Asked Questions about Castle Biosciences
When was Castle Biosciences founded?
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Castle Biosciences located?
Castle Biosciences is headquartered in Friendswood, United States. It is registered at Friendswood, Texas, United States.
Is Castle Biosciences a funded company?
Castle Biosciences is a funded company, having raised a total of $61.97M across 17 funding rounds to date. The company's 1st funding round was a Series F of $5.06M, raised on Mar 20, 2009.
How many employees does Castle Biosciences have?
As of Dec 31, 2024, the latest employee count at Castle Biosciences is 761.
What is the annual revenue of Castle Biosciences?
Annual revenue of Castle Biosciences is $332.07M as on Dec 31, 2024.
What does Castle Biosciences do?
Castle Biosciences was founded in 2008 and is headquartered in Friendswood, United States. Operations focus on the biotechnology sector, where prognostic assays for conditions such as uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme are developed. Additional tools like DecisionDx DiffDx-Melanoma for diagnosing melanocytic lesions are offered to support clinical decisions in oncology.
Who are the top competitors of Castle Biosciences?
Castle Biosciences's top competitors include Juno Therapeutics, DermTech and Poseida Therapeutics.
What products or services does Castle Biosciences offer?
Castle Biosciences offers DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix.
Is Castle Biosciences publicly traded?
Yes, Castle Biosciences is publicly traded on NASDAQ under the ticker symbol CSTL.
How many acquisitions has Castle Biosciences made?
Castle Biosciences has made 3 acquisitions, including AltheaDx, Castle Biosciences, and Previse.
Who are Castle Biosciences's investors?
Castle Biosciences has 5 investors. Key investors include SVB, BrightEdge, Industry Ventures, Health Quest Capital, and Mountain Group Partners.
What is Castle Biosciences's ticker symbol?
The ticker symbol of Castle Biosciences is CSTL on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.